Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 154

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 154
---
, and we expect to benefit from the well-defined regulatory guidelines 
 established by both U.S. and European regulatory authorities related to CAR-T cell therapy      
 manufacture. Accordingly, we have configured CER-T cell manufacturing processes to share        
 similarities with those employed in the production of CAR-T cells.                              |

| ● | Expand                                                                                            
 CER-1236 development activities to target solid tumors. We intend to expand the clinical          
 development of CER-1236 to include solid tumors. To this end, we plan on evaluating the potential 
 therapeutic utility of CER-1236 to treat NSCLC and ovarian cancer, indications for which          
 efficacious treatments have proven elusive. We believe CER-1236’s differentiated mechanism        
 of action enables the enhanced activity of a broader contingent of immune effector cells,         
 which may allow CER-1236 to achieve success treating cancers for which currently approved         
 CAR-T cell therapies have demonstrated little clinical benefit.                                   |

The Immune System and its Function

The immune system is a host
defense system comprising multiple structures and processes within an organism that protects against disease. As with other mammalian
species, the human immune system is segregated into two separate yet interconnected components, the innate immune system and the adaptive
immune system. The innate immune system is responsible for an immediate, non-specific response to infected or diseased cells. Triggering
its activation are pathogen-associated and damage-associated molecular patterns recognized by preconfigured pattern recognition receptors
which reside on the surface of various types of leukocytes, or white blood cells, that make up the innate immune system, including macrophages,
dendritic cells, eosinophils and natural killer (“NK”) cells. In addition to its direct participation in eliminating damaged
or diseased cells, certain components of the innate immune system function significantly as antigen-presenting cells (“APCs”)
promoting the activity of the adaptive immune system.

The adaptive immune system
is composed of special types of leukocytes known as T and B lymphocytes, also known as T and B cells, respectively. T cells participate
primarily in the cell-mediated immune response while B cells are involved in the humoral immune response. T cells are an essential
component of the adaptive immune system, targeting specific antigens and either destroying targeted cells directly or participating in
their destruction by activating other immune cells. T cells use T cell specific receptors to recognize antigens presented via major histocompatibility
complex (“MHC”) molecules on APCs. Through this mechanism, T